RecruitingPhase 2NCT04055428
NAUTICAL: Effect of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals
Studying Disorder of peptide metabolism
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Alabama at Birmingham
- Principal Investigator
- Pankaj Arora, MD, FAHAUniversity of Alabama at Birmingham
- Intervention
- Sacubitril, Valsartan 97-103 mg Oral Tablet(drug)
- Enrollment
- 200 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2027
Study locations (1)
- University of Alabama at Birmingham, Birmingham, Alabama, United States
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04055428 on ClinicalTrials.govOther trials for Disorder of peptide metabolism
Additional recruiting or active studies for the same condition.